AZN AstraZeneca PLC

By Rory Gallivan

LONDON--AstraZeneca PLC (AZN.LN) said Thursday the European Commission has given permission for the company's drug Lynparza to be marketed to some patients with ovarian cancer.

The drugs company said the commission, the European Union's executive arm, has granted marketing authorization for Lynparza capsules "as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA (Breast Cancer)-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy."

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires